<DOC>
	<DOCNO>NCT00059267</DOCNO>
	<brief_summary>Hepatitis B account approximately 5000 death per year United States . Liver transplantation offer hope patient develop end-stage liver disease . Early result liver transplantation hepatitis B poor recurrence rate 80 % 1-year survival 50 % . Recent study find preventive therapy use hepatitis B immune globulin ( HBIG ) antiviral medication lamivudine reduce recurrence rate roughly 30 % accompany improvement survival . However , HBIG give intravenous infusion high dos expensive , long-term use lamivudine associate drug resistance . Some study find preventive therapy use HBIG lamivudine may decrease recurrence rate le 10 % dose duration HBIG need use combination lamivudine clear . Adefovir , new antiviral medication , effective lamivudine resistant hepatitis B role liver transplantation uncertain risk kidney damage . Many study show risk recurrent hepatitis B related viral load transplant . Thus , may possible tailor preventive therapy accord risk . The aim study establish cost-effective preventive therapy recurrent hepatitis B liver transplantation .</brief_summary>
	<brief_title>Prevention Recurrent Hepatitis B After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<criteria>Patients await receive liver combine liverkidney transplantation hepatitis B include hepatitis B cirrhosis , hepatitis B liver cancer fulminant hepatitis B .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>